Development of a patient decision aid for COVID-19 vaccination with the Comirnaty vaccine

Abstract

Background SARS-CoV-2 has been responsible for a pandemic since the beginning of 2020. Vaccine arrival brings a concrete solution to fight the virus. However, vaccine hesitancy is high. In France, the first available vaccine was Comirnaty from Pfizer-BioNTech. Shared decision-making, based on tools such as patient decision aids (PtDAs), can help patients make an informed choice about vaccination with Comirnaty. Objective The French College of Teachers in General Practice (CNGE) aimed to create a PtDA for people who have to decide whether they will receive the Comirnaty vaccine. Methods Development of the PtDA was performed according to the International Patient Decision Aids Standards (IPDAS). The initial design was based on a literature review and semistructured interviews with 17 patients to explore and clarify patients’ expectations. A first draft of the PtDA was then alpha tested by a patient expert group and a physician expert group. The PtDA was finally beta tested in 14 prevaccine consultations. A steering group was consulted throughout the work. Patient support, community groups and the French National Authority for Health (HAS) were involved in the development process. Results A literature review identified one randomized trial on Comirnaty efficacy and safety. The first part of the PtDA allows patients to identify their own risk factors. The second part of the PtDA provides information on vaccination: benefits and risks, unknown data, and technical explanations about the mRNA vaccine. Conclusions We developed a PtDA to be used in primary care settings for shared decision-making regarding vaccination with Comirnaty.

Effect of information provision on parental intention toward COVID-19 vaccination for children: a nationwide survey experiment

“…Intervention studies to increase the acceptance of COVID-19 vaccination via information providing messages, behavioural nudges, virtual interventions, and videos have been reported 24 – 26 . Moreover, decision aids to support vaccination decision-making have been developed 27 , 28 . However, none of the previously reported interventions were targeted to parents with children and this study is distinguished as it was a nationwide study.…”

How far are the new wave of mRNA drugs from us? mRNA product current perspective and future development

“…mRNA is one of the most clinically promising frontiers of future biopharmaceuticals, and after years of development, heavyweight products have emerged, showing unprecedented applications in the treatment of metabolic diseases and the prevention of infectious diseases ( 113 ). The COVID-19 epidemic has brought mRNA vaccines to widespread public attention and brought about the rapid development of mRNA products, which are also becoming a focus of biopharmaceutical investment and a hotspot for pharmaceutical companies’ research and development.…”

What can we learn from rapidly developed patient decision aids produced during the covid-19 pandemic?

“…The French College of Teachers in General Practice has published a decision aid about whether to have the Pfizer-BioNTech vaccine. 22 The developers wanted to tackle vaccine hesitancy through shared decision making. They used the IPDAS criteria and a literature review and qualitative interviews with patients, focused on vaccine hesitancy, to develop the aid.…”

“…They cover vaccine decisions for the general population, people with rheumatologic diseases, and people who are pregnant or breastfeeding. The French College of Teachers in General Practice has published a decision aid about whether to have the Pfizer-BioNTech vaccine 22. The developers wanted to tackle vaccine hesitancy through shared decision making.…”